T1マッピングの実世界への応用
実世界コホートにおける疾患プロファイリングのためのT1マッピングの現状
The goal of this observational study is to create a comprehensive real-world spectrum of T1 mapping measurements across different heart conditions. We aim to establish reference values for how heart tissue characteristics vary in various diseases, which will help doctors better interpret these advanced MRI measurements in clinical practice. The main questions it aims to answer are:
What are the normal T1 mapping values for different heart diseases, and how do they compare to healthy hearts? Can we use the simpler "native T1" measurement (without contrast dye) instead of the more complex "ECV" measurement (which requires contrast dye) for diagnosis?
Patients with various myocardial conditions will undergo CMR T1 mapping scans. We will analyze the MRI images and clinical records to establish disease-specific reference ranges for T1 mapping parameters, and validate the diagnostic accuracy of T1 mapping
調査の概要
状態
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Huaying Zhang, Doctor
- 電話番号:86 13695310578
- メール:zhy_dreamer@163.com
研究場所
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100000
- 募集
- Fuwai Hospital, Chinese Academy of Medical Sciences
-
コンタクト:
- Huaying Zhang, Doctor
- 電話番号:86 13695310578
- メール:zhy_dreamer@163.com
-
-
参加基準
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
The study population comprises a diverse cohort of patients with a comprehensive spectrum of myocardial conditions, including Fabry disease, iron overload, atrial fibrillation, hypertension, aortic stenosis, chronic and acute myocardial infarction, hypertrophic, dilated, restrictive, and arrhythmogenic cardiomyopathies, acute and chronic myocarditis, cardiac amyloidosis, cardiac tumors, congenital heart disease, and cases of suspected transplant rejection. This population represents a wide array of pathophysiological processes affecting the myocardium, ensuring broad clinical relevance and generalizability of the study findings.
説明
Inclusion Criteria:
-
Adult patients (≥18 years) with clinically diagnosed myocardial diseases based on current international guidelines.
-
Specific disease categories include:
- Cardiomyopathies (HCM, DCM, RCM, ACM)
- Infiltrative disorders (cardiac amyloidosis, Fabry disease)
- Inflammatory conditions (acute/chronic myocarditis)
- Ischemic heart disease (acute/chronic MI)
- Valvular heart disease (aortic stenosis)
- Arrhythmic conditions (atrial fibrillation)
- Metabolic disorders (iron-overload)
- Neoplastic conditions (cardiac tumors)
- Congenital heart disease
- Post-transplant evaluation
-
All diagnoses must be confirmed using established guideline-based criteria:
- Echocardiographic parameters meeting disease-specific cutoffs
- Cardiac MRI findings consistent with current consensus criteria
- Laboratory biomarkers supporting respective diagnoses
- Histopathological confirmation when clinically indicated
Exclusion Criteria:
- Presence of multiple cardiomyopathy diseases or risk factors simultaneously
- Contraindications to CMR examination
- Poor image quality precluding accurate T1 mapping analysis
- Incomplete clinical data for definitive diagnosis confirmation
- Pregnancy or lactation
- Inability to provide informed consent
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Healthy Controls
CMR criteria: Anatomically intact cardiac structures: LVEF, ventricular volumes, and wall thickness within sex- and BSA-adjusted reference ranges (LVEF ≥55%, LVEDVi <82 mL/m² for females, <97 mL/m² for males); Absence of pathological tissue characteristics (negative LGE); Normal hemodynamic profile: Competent valvular function without hemodynamically significant regurgitation or stenosis. Clinical exclusion criteria: No history of coronary artery disease, inflammatory cardiomyopathy, or electrophysiological abnormalities requiring intervention |
Participants in this arm undergo a single, standardized cardiac MRI scan with gadolinium-based contrast agent. |
|
Myocardial Diseases
Patients with various myocardial diseases including Fabry disease, Iron-overload, atrial fibrillation (AF), hypertension, aortic stenosis (AS), chronic myocardial infarction (MI), acute MI, hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), restrictive cardiomyopathy (RCM), arrhythmogenic cardiomyopathy (ACM), acute myocarditis, chronic myocarditis, cardiac amyloidosis, cardiac tumor, congenital heart disease, and suspected transplant rejection. |
Participants in this arm undergo a single, standardized cardiac MRI scan with gadolinium-based contrast agent. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
T1マッピング値の範囲
時間枠:登録から最後のT1マッピング検査完了まで、最大5年間評価
|
登録から最後のT1マッピング検査完了まで、最大5年間評価
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。